As of October 1, 2020 esteemed tumor immunologist Prof Dr Jolanda de Vries becomes a member of the scientific advisory board.  Jolanda de Vries is head of the department of Tumor Immunology at Radboudumc, Nijmegen, the Netherlands.

Professor de Vries is an internationally renowned authority in the field of cancer immunotherapy. De Vries is recognised for many years as a leading figure in tumor immunology, in particular dendritic cells, cancer immunotherapy and imaging immune responses in cancer patients. 

De Vries was amongst the first worldwide who introduced tumour antigen-loaded dendritic cell (DC)-based vaccines in the clinic. She was the first to track the migratory behaviour of dendritic cells in patients, demonstrating how important the route of administration can be to maximize the capacity of cellular vaccines to boost anti-cancer immunity.

Her work gets cited very frequently. Her international scientific recognition is underscored by the invitations to lead and participate in assessing international grant applications, site visits of institutes that are aimed at boosting translational research and collaborations with companies that aim at implementing immunotherapy.